



FOR IMMEDIATE RELEASE

April 21, 2022

EnteroTrack CMO receives distinguished clinical award

In recognition of his seminal contributions to the field of Eosinophilic Gastrointestinal Diseases, Dr. Glenn Furuta received the [North American Society for Pediatric Gastroenterology, Hepatology and Nutrition](#) (NASPGHAN) 2021 Harry Shwachman Award.

According to the Rare Diseases Clinical Research Network, the Shwachman Award recognizes “outstanding achievements in the field of pediatric gastroenterology, hepatology and nutrition.”

“I am privileged to be able to serve our medical community in a way that makes our care of patients with gastrointestinal diseases better,” said Dr. Furuta. “This award is symbolic of the collaborative impacts of many people. Bringing the EnteroTracker® to clinical use is longtime goal that bridges basic and clinical research to improve lives of patients with GI diseases.”

“We at EnteroTrack are proud of Dr. Furuta’s achievements as a clinician scientist,” said Robin Shandas, CEO of EnteroTrack. “Indeed, it is from of these achievements that EnteroTrack was born. Our goal is to make sure Dr. Furuta’s innovative ideas to make life better for patients with eosinophilic diseases become clinical reality.”

About EnteroTrack

EnteroTrack develops simple-to-use, minimally invasive technologies to sample gastrointestinal (GI) mucosal content that can be assayed for various biomarkers of disease. The company’s platform technology, the EnteroTracker® is initially being used to support clinical monitoring of Eosinophilic Esophagitis in adults and children without need for sedation, advanced training, or complex procedures.

Clinical studies evaluating the utility of the EnteroTracker® for additional applications including Esophageal Adenocarcinoma, Barrett’s Esophagus, GERD, GI microbiome, food allergy testing, and others are currently underway.

Visit www.enterotrack.com or contact Brookelynn Stillwell (brookelynn.stillwell@enterotrack.com) for more information.